Status:
UNKNOWN
The Level of Blood Brain Barrier Damage Biomarker in Acute Ischemic Stroke
Lead Sponsor:
Ji Xunming,MD,PhD
Conditions:
Ischemic Stroke
Eligibility:
All Genders
18-80 years
Brief Summary
Hemorrhagic transformation is a common complication of acute ischemic stroke patients . BBB damage is regarded as a major pathophysiological mechanism of hemorrhagic transformation. So, the investigat...
Detailed Description
Hemorrhagic transformation is a common complication of acute ischemic stroke patients . BBB injury often occurs in the early stage of ischemic stroke, leading brain tissue edema or even hemorrhagic tr...
Eligibility Criteria
Inclusion
- Enrolled patients aged 18-80years.
- Acute ischemic stroke
- Informed consent obtained.
Exclusion
- Tumor stroke or hemorrhagic stroke or hemorrhagic cerebral infarction on admission.
- Stroke or serious head trauma within the previous 3 months
- inflammatory or infectious diseases, cancer, coagulation disturbance disease and severe renal and liver failure
- blood sample occurred hemolysis or cloudy.
- Incomplete clinical data
- Platelet count of less than 100,000 per cubic millimeter
- Received oral anticoagulation therapy preceding the onset of stroke and INR greater than 1.7 or prothrombin times greater than 15 seconds
- Pregnant or breast-feeding women
- Patients being enrolled or having been enrolled in other clinical trial -
Key Trial Info
Start Date :
March 10 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2025
Estimated Enrollment :
1000 Patients enrolled
Trial Details
Trial ID
NCT05321225
Start Date
March 10 2022
End Date
December 31 2025
Last Update
April 15 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Xuanwu hospital;Capital Medical University
Beijin, XI Cheng District, China, 100053